CDER Division of Drug Labeling Compliance
Executive Summary
Deputy Director Mary Richardson begins 60-day detail as Division of Scientific Investigations deputy director Feb. 20. Former scientific investigations deputy director Ross Laderman has left FDA for Guilford Pharmaceuticals ("The Pink Sheet" Feb. 7, In Brief). Prescription Drug Compliance Branch Chief Frank Fazzari is acting director of the labeling compliance division until Richardson returns April 30. The division's director Richard Chastonay retired March 1